Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580012 | 0.85 | CYP24A1 (0.48) | CYP24A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL5197570 | 0.83 | CNR2 (0.47) | CYP24A1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL580335 | 0.80 | CYP24A1 (0.39) | CYP24A1ALDH1A1GAALMNAHTT | |
| SCHEMBL579971 | 0.80 | CYP24A1 (0.39) | CYP24A1ALDH1A1GAALMNAHTT | |
| SCHEMBL580494 | 0.74 | ABCB1 (0.44) | GAAPOLBTAS1R3TAS1R1 | |
| SCHEMBL28664196 | 0.71 | ALDH1A1 (0.58) | CYP24A1ALDH1A1GAAPOLB | |
| SCHEMBL605143 | 0.68 | ALDH1A1 (0.51) | CYP24A1ALDH1A1GAALMNA | |
| SCHEMBL17023782 | 0.68 | CYP24A1 (0.48) | CYP24A1ALDH1A1GAALMNAHTT | |
| SCHEMBL29090841 | 0.68 | CYP24A1 (0.42) | CYP24A1ALDH1A1PDE4DGAALMNA | |
| SCHEMBL4001032 | 0.68 | ALDH1A1 (0.41) | CYP24A1ALDH1A1GAALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633695-B1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-1633695-A4 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7141696-B2 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1633695-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | Bridge Pharma, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105692-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248987-A1 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | MYLK, TNNC1, MYLK2 | CYP24A1 2421/4885ALDH1A1 230/4885PDE4A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.